Biosimilars and Pharma Innovations

October 26-27, 2020
Dubai, UAE

Consequences of Brexit on Biosimilars

With Europe that made-up because of the uptake of biosimilars over a decade agone, the results of Brexit would be doubtless tougher on UK. Presently UK isn't to any extent further guaranteed to follow the foundations of EMA. Additionally analysis grants from Innovative Medicines Initiative and Horizon 2020 would no a lot of be offered to UK. All the same, EMA has its headquarters in London, UK. The so arising complications would positively have sure consequences on the Biosimilars state of affairs in UK and EU.

Brexit- Pros and Cons to European pharma market

Post Brexit changes in biosimilars regulation in UK

Fate of biosimilars clinical trials in UK

Research funding from European organizations to UK based research laboratories

Be a member and support us

Visit the App Store to see our app.

Follow us

Authorization Policy

By registering for the conference you grant permission to Conference Series LLC Ltd to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.